OKYO Pharma Reports New Phase 2 Data Demonstrating Meaningful Improvements in Patient-Reported Quality of Life Outcomes with Urcosimod in Neuropathic Corneal Pain

Summary by AI BETAClose X

OKYO Pharma announced positive exploratory Phase 2a data for urcosimod in neuropathic corneal pain, demonstrating meaningful improvements in patient-reported quality of life alongside previous pain reduction findings. In the trial, six patients treated with 0.05% urcosimod showed significant improvements in enjoying life/relationships (mean change -4.5 vs. 0 for placebo), mood (mean change -1.5 vs. -0.5), and reduced time spent thinking about eye pain (mean change -3.0 vs. -1.5). These results, which will be presented at ARVO 2026, reinforce urcosimod's potential holistic therapeutic profile and support the company's plans for larger confirmatory trials, including a Phase 2b/3 study.

Disclaimer*

UK 100

Latest directors dealings